Direct-to-Consumer Genetic Testing: Finding a Clear Path Forward.
Regulatory compliance in the direct-to-consumer genetic testing market is highly sophisticated as there are numerous federal, state, and ethical barriers to entry. In 2010, amid an underregulated market, 23andMe sought to do what few companies in the medical industry had attempted before-disregard the guidance and requests of the US Food and Drug Administration. This regulatory strategy effectively destined the company's Personal Genome Service for failure; however, the company changed course and has been granted several regulatory clearances. This exemplifies the importance of a healthy relationship with regulatory agencies, although challenges remain. The DTC industry continues to have a perplexing regulatory framework at both the federal and state level. There are also ethical concerns with the monetization of deidentified genetic health information, as genetic data have an inherent level of identifiability and are not fully protected by the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule in these scenarios. Although some DTC tests are now cleared in the United States, the concern that a learned intermediary is needed for interpretation of results remains. The regulatory oversight of this market will need to continue to develop to ensure the protection of consumer health and privacy.
['Seward|Brendan|B|0000-0002-9000-5360']
D000067108:Direct-To-Consumer Screening and Testing D030661:Genetic Privacy D005820:Genetic Testing D020408:Health Insurance Portability and Accountability Act D006801:Humans D014481:United States D014486:United States Food and Drug Administration
direct-to-consumer genetic testing ethics laboratory developed tests regulatory science